HRP20080349T3 - Zrna premazana enteričkom smjesom koja sadrže iksabepilon - Google Patents

Zrna premazana enteričkom smjesom koja sadrže iksabepilon

Info

Publication number
HRP20080349T3
HRP20080349T3 HR20080349T HRP20080349T HRP20080349T3 HR P20080349 T3 HRP20080349 T3 HR P20080349T3 HR 20080349 T HR20080349 T HR 20080349T HR P20080349 T HRP20080349 T HR P20080349T HR P20080349 T3 HRP20080349 T3 HR P20080349T3
Authority
HR
Croatia
Prior art keywords
enterical
ixabepilone
mixture containing
coated
grain coated
Prior art date
Application number
HR20080349T
Other languages
English (en)
Croatian (hr)
Inventor
Ullah Ismat
James Wiley Gary
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20080349T3 publication Critical patent/HRP20080349T3/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HR20080349T 2004-11-18 2005-11-17 Zrna premazana enteričkom smjesom koja sadrže iksabepilon HRP20080349T3 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62897004P 2004-11-18 2004-11-18
PCT/US2005/041736 WO2006055740A1 (en) 2004-11-18 2005-11-17 Enteric coated bead comprising ixabepilone, and preparation thereof

Publications (1)

Publication Number Publication Date
HRP20080349T3 true HRP20080349T3 (hr) 2009-01-31

Family

ID=35976527

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20080349T HRP20080349T3 (hr) 2004-11-18 2005-11-17 Zrna premazana enteričkom smjesom koja sadrže iksabepilon

Country Status (25)

Country Link
US (1) US20060153917A1 (https=)
EP (2) EP1817013B1 (https=)
JP (1) JP2008520696A (https=)
KR (1) KR20070084325A (https=)
CN (1) CN101083978A (https=)
AR (1) AR052142A1 (https=)
AT (1) ATE397442T1 (https=)
AU (1) AU2005306464A1 (https=)
BR (1) BRPI0518286A2 (https=)
CA (1) CA2588400A1 (https=)
DE (1) DE602005007376D1 (https=)
DK (1) DK1817013T3 (https=)
ES (1) ES2306278T3 (https=)
HR (1) HRP20080349T3 (https=)
IL (1) IL183116A0 (https=)
MX (1) MX2007005763A (https=)
NO (1) NO20072388L (https=)
PE (1) PE20061058A1 (https=)
PL (1) PL1817013T3 (https=)
PT (1) PT1817013E (https=)
RU (1) RU2349319C1 (https=)
SI (1) SI1817013T1 (https=)
TW (1) TW200631609A (https=)
WO (1) WO2006055740A1 (https=)
ZA (1) ZA200703955B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101091725A (zh) 2006-06-23 2007-12-26 天津天士力制药股份有限公司 一种中药颗粒及其制备方法
US20110217426A1 (en) * 2010-03-04 2011-09-08 Perry Stephen C Enteric coating composition
ME02464B (me) 2010-03-12 2017-02-20 Genzyme Corp Kombinovana terapija za lečenje raka dojke
WO2012047802A2 (en) * 2010-10-01 2012-04-12 The Johns Hopkins University Systems and methods for high-throughput microfluidic bead production
AU2012214553B2 (en) 2011-02-11 2015-07-09 Sociétés des Produits Nestlé S.A. Multiparticulate L-menthol formulations and related methods
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
ES2706152T3 (es) 2013-04-23 2019-03-27 Zx Pharma Llc Composición entérica de múltiples partículas revestida con subrevestimiento proteico

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713246A (en) * 1984-03-19 1987-12-15 Bristol-Myers Company Etoposide oral dosage form
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
DK1186606T4 (da) * 1995-11-17 2011-12-05 Biotechnolog Forschung Gmbh Epothilonderivater, deres fremstilling og anvendelse
JP4090529B2 (ja) * 1996-01-24 2008-05-28 フロイント産業株式会社 乳糖の球形粒及びその製造方法
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US6251911B1 (en) * 1996-10-02 2001-06-26 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
DK1367057T3 (da) * 1996-11-18 2009-01-19 Biotechnolog Forschung Gmbh Epothiloner E og F
FR2759293B1 (fr) * 1997-02-11 1999-04-30 Ethypharm Lab Prod Ethiques Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie
PT975638E (pt) * 1997-02-25 2002-12-31 Biotechnolog Forschung Mbh Gbf Epothilons modificados nas cadeias laterais
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6399638B1 (en) * 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6498257B1 (en) * 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
DE19826988A1 (de) * 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
DE69925293T2 (de) * 1998-10-01 2006-01-26 Powderject Research Ltd. Sprühbeschichtete mikropartikel für nadellose spritzen
YU59001A (sh) * 1999-02-18 2005-07-19 Schering Ag. 16-halogen-epotilon-derivati, postupak za njihovo dobijanje i njihova farmaceutska primena
BR0008379A (pt) * 1999-02-22 2002-09-24 Biotechnolog Forschung Gmbh Epotilonas modificadas em c-21
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
IL149030A0 (en) * 2000-08-09 2002-11-10 Panacea Biotec Ltd Pharmaceutical compositions containing rifampicin, isoniazid or combinations thereof
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
EP1319011B1 (de) * 2000-09-22 2012-12-05 Helmholtz-Zentrum für Infektionsforschung GmbH Triazolo-epothilone
EP1191127B1 (de) 2000-09-26 2004-10-13 Enthone-OMI (Deutschland) GmbH Verfahren zur selektiven Metallisierung dielektrischer Materialien
IL156580A0 (en) * 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
HU229349B1 (en) * 2001-01-25 2013-11-28 Bristol Myers Squibb Co Methods for preparation of pharmaceutical composition containing epothilone analogs useful for treatment of cancer
PL363363A1 (en) * 2001-02-20 2004-11-15 Bristol-Myers Squibb Company Epothilone derivatives for the treatment of refractory tumors
BR0207487A (pt) * 2001-02-20 2004-08-10 Brystol Myers Squibb Company Método de tratamento de tumores em mamìferos e uso de compostos de epotilona
WO2002072085A1 (en) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
MXPA03010909A (es) * 2001-06-01 2004-02-17 Bristol Myers Squibb Co Derivados de epotilona.
JP4645789B2 (ja) * 2001-06-18 2011-03-09 Ｊｓｒ株式会社 ネガ型感放射線性樹脂組成物
AU2003218107A1 (en) * 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
SI1483251T1 (sl) * 2002-03-12 2010-03-31 Bristol Myers Squibb Co C cian epotilonski derivati
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
WO2003105828A1 (en) * 2002-06-14 2003-12-24 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
EP1539111A1 (en) * 2002-08-05 2005-06-15 DSM IP Assets B.V. Oral dosage forms of water insoluble drugs and methods of making the same
AU2003279911A1 (en) * 2002-10-09 2004-05-04 Kosan Biosciences, Inc. Therapeutic formulations
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof

Also Published As

Publication number Publication date
ES2306278T3 (es) 2008-11-01
SI1817013T1 (sl) 2008-12-31
PT1817013E (pt) 2008-08-07
ZA200703955B (en) 2008-08-27
MX2007005763A (es) 2007-07-20
EP1958625A1 (en) 2008-08-20
AU2005306464A1 (en) 2006-05-26
DK1817013T3 (da) 2008-10-13
DE602005007376D1 (de) 2008-07-17
US20060153917A1 (en) 2006-07-13
CN101083978A (zh) 2007-12-05
WO2006055740A1 (en) 2006-05-26
PL1817013T3 (pl) 2009-01-30
IL183116A0 (en) 2007-09-20
RU2349319C1 (ru) 2009-03-20
AR052142A1 (es) 2007-03-07
NO20072388L (no) 2007-06-14
EP1817013B1 (en) 2008-06-04
ATE397442T1 (de) 2008-06-15
CA2588400A1 (en) 2006-05-26
JP2008520696A (ja) 2008-06-19
HK1106713A1 (en) 2008-03-20
EP1817013A1 (en) 2007-08-15
KR20070084325A (ko) 2007-08-24
BRPI0518286A2 (pt) 2008-11-11
TW200631609A (en) 2006-09-16
PE20061058A1 (es) 2006-10-13

Similar Documents

Publication Publication Date Title
ECSP077402A (es) Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica
PE20030638A1 (es) Formulacion granular de montelukast sodico
NO20032252L (no) Piperazinylpyrazinforbindelser som agonist eller antagonist av serotonin 5HT-2-reseptor
AU2003246811A1 (en) Terphenyl derivatives, preparation thereof, compositions containing same
ATE429907T1 (de) Zusammensetzungen mit verzögerter freigabe enthaltend venlafaxinhydrochlorid als wirkstoff
AR058433A1 (es) Derivado de 1,1-dioxido de 1,4-benzotiazepina ,procedimiento para su preparacion ,medicamentos que comprenden este compuesto y su uso
WO2007048065A3 (en) Pyrimidinones as casein kinase ii (ck2) modulators
SG149887A1 (en) Coating composition having surface depolluting properties
UA91027C2 (ru) ИНГИБИТОРЫ ВЗАИМОДЕЙСТВИЯ МЕЖДУ MDM2 И р53
BRPI0719395C1 (pt) tablete revestido de filme
ATE479687T1 (de) Kinaseinhibitoren
WO2004096134A3 (en) Substituted 1,4-diazepines and uses thereof
EP1340755A4 (en) AGENT WITH EFFECT AGAINST HELICOBACTER
GEP20063767B (en) Spiro-Hydantoin Compounds Useful as Anti-Inflammatory Agents
NO20080002L (no) Formuleringer av konjugerte ostrogener og bazedoxifen
YU87101A (sh) Derivati benzena, postupak za njihovo dobijanje i farmaceutski preparati koji ih sadrže
EA200700042A1 (ru) РАСПЫЛЯЕМЫЕ В ВИДЕ АЭРОЗОЛЯ СУСПЕНЗИОННЫЕ КОМПОЗИЦИИ С TG 227ea ИЛИ TG 134a В КАЧЕСТВЕ ПРОПЕЛЛЕНТА
BR0202491A (pt) Forma de dosagem de núcleo macio, de revestimento frágil
HRP20080349T3 (hr) Zrna premazana enteričkom smjesom koja sadrže iksabepilon
WO2004017104A3 (en) Retroreflective aerosol coating composition and methods of making and using thereof
MXPA05008161A (es) Composicion que comprende una mezcla de principios activos, y metodo de preparacion.
WO2003047520A3 (en) SUBSTITUTED AMINO METHYL FACTOR Xa INHIBITORS
DE60323474D1 (de) Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin
JPH10219144A5 (https=)
PL375986A1 (en) Methods for coating substrates for pharmaceutical uses with a mixture of two film-forming coating agents